Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HMS5552 in Hepatic Impairment
NCT04426708Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dorzagliatin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hua Medicine. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last quantifiable concentration and 1 more. Started Feb 2019; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04426708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426708.